Logo image
ATGL-mediated fat catabolism regulates cardiac mitochondrial function via PPAR-Î ± and PGC-1
Journal article   Open access   Peer reviewed

ATGL-mediated fat catabolism regulates cardiac mitochondrial function via PPAR-Î ± and PGC-1

G Haemmerle, T Moustafa, G Woelkart, S Büttner, A Schmidt, T Van De Weijer, M Hesselink, D Jaeger, P C Kienesberger, K Zierler, …
Nature Medicine, Vol.17(9), pp.1076-1085
2011
pdf
PDF - Author's Accepted Version976.55 kBDownloadView
Accepted VersionPDF - Author Accepted Version Open Access
url
https://doi.org/10.1038/nm.2439View
Published Version

Abstract

cardiomyopathies cardiovascular biology fat metabolism metabolic disorders
Peroxisome proliferator-activated receptors (PPARs) are nuclear hormone receptors that regulate genes involved in energy metabolism and inflammation. For biological activity, PPARs require cognate lipid ligands, heterodimerization with retinoic X receptors, and coactivation by PPAR-γ coactivator-1α or PPAR-γ coactivator-1β (PGC-1α or PGC-1β, encoded by Ppargc1a and Ppargc1b, respectively). Here we show that lipolysis of cellular triglycerides by adipose triglyceride lipase (patatin-like phospholipase domain containing protein 2, encoded by Pnpla2; hereafter referred to as Atgl) generates essential mediator(s) involved in the generation of lipid ligands for PPAR activation. Atgl deficiency in mice decreases mRNA levels of PPAR-α and PPAR-δ target genes. In the heart, this leads to decreased PGC-1α and PGC-1β expression and severely disrupted mitochondrial substrate oxidation and respiration; this is followed by excessive lipid accumulation, cardiac insufficiency and lethal cardiomyopathy. Reconstituting normal PPAR target gene expression by pharmacological treatment of Atgl-deficient mice with PPAR-α agonists completely reverses the mitochondrial defects, restores normal heart function and prevents premature death. These findings reveal a potential treatment for the excessive cardiac lipid accumulation and often-lethal cardiomyopathy in people with neutral lipid storage disease, a disease marked by reduced or absent ATGL activity. © 2011 Nature America, Inc. All rights reserved.

Details

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types
Domestic collaboration
International collaboration
Web Of Science research areas
Biochemistry & Molecular Biology
Cell Biology
Medicine, Research & Experimental

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: InCites

Logo image